The conversation discusses hair loss treatments like Minoxidil and Finasteride, with users sharing experiences and suggesting alternatives like topical applications and hair systems. It also touches on personal beliefs and perspectives on faith and life challenges.
Amplifica's AMP-303 showed a modest increase in hair growth, but results were inconsistent and potentially misleading. Hyaluronic acid and osteopontin are being explored for hair growth, with varying effects on different hair types and conditions.
An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.
Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.
Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.
CB-03-01 is considered too costly and lacks a proper delivery method, making it less viable compared to RU58841, which has shown effectiveness with minimal side effects. Finasteride caused a drop in libido for one user.
Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.
A humorous discussion about hair loss treatments, specifically mentioning the use of 5mg of Dutasteride. The conversation includes jokes about the effectiveness of the treatment.
The conversation discusses the frustration over the unavailability of 2.5mg dutasteride soft gels, with some users suggesting higher doses for better scalp DHT suppression. Concerns about side effects and the necessity of DHT are debated, with some users advocating for alternative treatments like RU58841 and oral minoxidil.
Finasteride users discuss potential side effects, including Post Finasteride Syndrome (PFS), with varying opinions on its legitimacy and impact. Some users report side effects like changes in semen consistency and reduced pre-ejaculate, while others emphasize the rarity and reversibility of side effects.
Sprocketshead asks if pyrilutamide can be applied with minoxidil, and inquires about its consistency and odor. They want to know if it's more high maintenance than topical minoxidil.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.
The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.
Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.
Pyrilutamide, a hair loss treatment, is undergoing clinical trials in China and may be available in a few years. Users discuss the possibility of obtaining it early through group buys and synthesis by labs.
The new formulation includes minoxidil, finasteride, redensyl, caffeine, and propacil, and removes alcohol. The user is concerned about potential hair shedding due to the change in ingredients.
The conversation discusses skepticism about DHT blocker supplements for hair loss, with many users recommending proven treatments like finasteride and minoxidil instead. Some users shared personal experiences with alternative treatments like beta-sitosterol and saw palmetto, noting side effects and limited effectiveness.
PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.
Adding caffeine to topical minoxidil is unlikely to enhance its effectiveness, with most users agreeing it has minimal impact. The main treatments discussed are minoxidil and finasteride, with some users adding other ingredients like azelaic acid and retinol.
A user experienced libido issues after using finasteride for five months, with elevated prolactin and estradiol levels. The discussion includes differing opinions on whether these symptoms are due to hormonal imbalances or post-finasteride syndrome.
The conversation is about hair loss treatments. The user considers using a foam with Saw palmetto, caffeine, and EGCG, but another user suggests just using finasteride.
The conversation is about someone switching from Minoxidil and Finasteride to Redensyl, Procapil, and Capixyl serums due to anxiety over potential side effects, and they are inquiring about others' regrowth experiences with these serums. Some doctors in India have prescribed these serums, and the person knows others who are satisfied with the results.
People discuss whether it's appropriate to suggest hair loss treatments like finasteride or minoxidil to others, especially young individuals. Opinions vary, with some advocating for sharing information and others cautioning against unsolicited advice due to potential side effects and personal sensitivities.
The post and conversation discuss KX-826 (pyrilutamide) for hair loss treatment, with positive remarks about its advertising and authenticity in China. The user changed their perspective after further research and seeing genuine advertising.
The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.
A user is seeking a trusted supplier for RU58841 in the UK, expressing doubts about their current source, rudirect, and considering Anagenic and receptorchem. They are asking for recommendations for other suppliers.